Hypromellose
GET
/api/v1/drug/hypromelloseMechanism of action
Sourced from openFDAMechanism-of-action class: Demulcent Activity.
Indications
Sourced from openFDA- Uses Temporarily relieves burning and irritation due to dryness of the eye. discomfort due to minor irritations of the eye or to exposure to wind or sun.
Dosage & administration
Sourced from openFDADirections instill 1 or 2 drops in the affected eye(s) as needed
Warnings & precautions
Sourced from openFDAFor external use only. Do not use if solution changes color or becomes cloudy. When using this product do not touch tip of container to any surface to avoid contamination. replace cap after using. remove contact lenses before using. Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye. condition worsens or persists for more than 72 hours. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away 1-800-222-1222.
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
2,703 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Eye Irritation2137.9%
- 2Eye Pain1676.2%
- 3Vision Blurred1485.5%
- 4Headache1314.8%
- 5Drug Ineffective1164.3%
- 6Nausea1134.2%
- 7Dizziness1124.1%
- 8Dyspnoea1104.1%
- 9Ocular Hyperaemia1033.8%
- 10Diarrhoea983.6%
- 11Vomiting953.5%
- 12Fatigue873.2%
- 13Malaise823.0%
- 14Pain792.9%
- 15Confusional State782.9%
Literature
Recent PubMed references pinned to Hypromellose as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Development of HPMC-Based Hard Capsules with Rapid Disintegration Across Simulated Gastrointestinal pH Conditions: Formulation Design, Process Optimization, and Disintegration Mechanism of the HPMC/GG/ι-C Ternary System.Marine drugs · 2026 · Dong Y, Ye S, Hong X, et al.PMID 42188297DOI 10.3390/md24050162
- Hydrophobic-Enhanced HPMC/Chitosan/Beeswax Edible Coatings Incorporating Fruit and Vegetable Polyphenol Extracts for Mango Fruit Preservation.Journal of food science · 2026 · Iqbal SZ, Bashir N, Ali S, et al.PMID 42169236DOI 10.1111/1750-3841.71141
- 3D printed 13-93B3 borate bioactive glass/hydroxypropyl methyl cellulose/gelatin scaffolds with cerium oxide submicrometric particles for potential bone regeneration.Biomedical materials (Bristol, England) · 2026 · İyigün S, Güven A, Aslan C, et al.PMID 42068995DOI 10.1088/1748-605X/ae67c9
- Bigel based on monoglyceride and hydroxypropyl methylcellulose: preparation, characterization, and application in the release of ferulic acid.Journal of the science of food and agriculture · 2026 · Valizade F, Kalantari G, Abdolmaleki K, et al.PMID 42066030DOI 10.1002/jsfa.70683
- Effects of spray-freeze-dried microcapsules with different proportions of hydroxypropyl methylcellulose and whey protein isolate on the viability and release property of probiotics.Food chemistry · 2026 · Zhang X, Liu T, Zhao J, et al.PMID 41967404DOI 10.1016/j.foodchem.2026.149202
- On-demand amorphous calcium phosphate-mediated regeneration of dentin and enamel using ion-regulated hydroxypropyl methylcellulose and carboxymethyl chitosan hydrogels.Carbohydrate polymers · 2026 · Cui Z, Liu Z, Zhang Z, et al.PMID 41943389DOI 10.1016/j.carbpol.2026.125170
- Hydroxypropyl Methylcellulose as a Functional Dietary Fiber Preserves Intestinal Barrier Integrity via NF-κB Modulation Under Inflammatory Conditions.Journal of medicinal food · 2026 · Kim M, Cho CH, Kim S, et al.PMID 41879168DOI 10.1177/1096620X261430170
- Involvement of the spleen in the anti-prion activity of hydroxypropyl methylcellulose in mice.Scientific reports · 2026 · Teruya K, Oguma A, Nishizawa K, et al.PMID 41844715DOI 10.1038/s41598-026-42969-z
Clinical trials
The 10 most recently updated of 589 ClinicalTrials.gov registrations naming Hypromellose as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)Recruiting · Phase 1 · Phase 2 · Interventional · 230 enrolled · Merck Sharp & Dohme LLCNCT05319730updated 2026-06-12
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionRecruiting · Phase 2 · Interventional · 100 enrolled · AbbVieNCT06365853updated 2026-06-12
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Recruiting · Phase 1 · Phase 2 · Interventional · 32 enrolled · Merck Sharp & Dohme LLCNCT06637423updated 2026-06-12
- Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular HypertensionRecruiting · Phase 4 · Interventional · 50 enrolled · Indiana UniversityNCT07588152updated 2026-06-11
- Randomized Clinical Trial of Artificial Tears With and Without Preservatives in Patients With Dry Eye DiseaseNot yet recruiting · Phase 4 · Interventional · 80 enrolled · Pokhara Academy of Health Sciences, Western Regional HospitalNCT07635849updated 2026-06-10
- Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLTActive not recruiting · Phase 4 · Interventional · 70 enrolled · East Coast Institute for ResearchNCT06865144updated 2026-06-10
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland DysfunctionRecruiting · Phase 4 · Interventional · 48 enrolled · University of Alabama at BirminghamNCT07224529updated 2026-06-09
- Effect of Metformin, a Drug Used to Treat Diabetes, vs PlaceboActive not recruiting · Phase 4 · Interventional · 150 enrolled · University of California, Los AngelesNCT05949008updated 2026-06-08
- 0.01% and 0.025% Atropine Eye Drops Combined Auricular Acupoint Stimulation on Myopia Control and Corneal Endothelium ChangeEnrolling by invitation · Interventional · 420 enrolled · China Medical University HospitalNCT07537166updated 2026-06-04
- Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaRecruiting · Phase 2 · Phase 3 · Interventional · 576 enrolled · AbbVieNCT07592273updated 2026-06-04
Frequently asked questions
- How does Hypromellose work?
- Mechanism-of-action class: Demulcent Activity.
- What is Hypromellose used for?
- According to FDA labeling, Hypromellose carries indications including: Uses Temporarily relieves burning and irritation due to dryness of the eye. discomfort due to minor irritations of the eye or to exposure to wind or sun.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Hypromellose?
- Hypromellose is classified as Viscoelastic substances, Demulcent Activity.
- What are the brand names for Hypromellose?
- Hypromellose is marketed under brand names including Bion Tears, Cellugel, GenTeal, Goniosoft, Goniovisc, Isopto Alkaline, Tears Naturale Forte.
Note. Data for
hypromellose is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.